Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka AkcyjnafiledCriticalRead-Gene Spółka Akcyjna
Priority to PL439314ApriorityCriticalpatent/PL439314A1/en
Publication of PL439314A1publicationCriticalpatent/PL439314A1/en
Przedmiotem zgłoszenia jest sposób określenia ryzyka raka, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia kadmu w próbce biologicznej osoby badanej, przy czym stężenie kadmu wskazuje na znacząco obniżone ryzyko: rozwoju raka piersi w przypadku występowania wysokiej wartości stężenia kadmu we krwi, szczególnie powyżej 0,59 µg/l.The subject of the application is a method of determining the risk of cancer, characterized by the fact that it includes the quantification of the concentration of cadmium in a biological sample of the tested person, where the concentration of cadmium indicates a significantly reduced risk of: developing breast cancer in the case of high levels of cadmium in the blood, especially above 0 , 59 µg / l.
PL439314A2018-05-172018-05-17Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood
PL439314A1
(en)
Human monoclonal antilipoarabinomannan (anti-lam) antibody, kit for detecting at least one lam epitope, method for diagnosing an active tuberculosis infection in an individual, method for treating a tuberculosis infection in an individual, human anti-lam monoclonal antibody and lam preconcentration method from a biological sample
Method for determining the risk of cancers in women, depending on concentration of zinc in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations
Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations
Method for determining the risk of cancers depending on concentration of selenium in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations